Is fat anterior to the psoas muscle below the lower pole of the left kidney a common site for lymph node metastasis from T1a renal cell carcinoma (kidney cancer)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Fat anterior to the psoas muscle below the lower pole of the left kidney is not a common site for lymph node metastasis from T1a kidney cancer. T1a kidney cancers are small tumors (less than 4 cm) confined to the kidney, and they generally have a low risk of metastasis, with less than 5% spreading to lymph nodes 1. When kidney cancer does metastasize to lymph nodes, it typically follows predictable drainage patterns, primarily involving the hilar, para-aortic, and paracaval lymph nodes rather than fat deposits anterior to the psoas muscle. The location described is more likely to represent normal retroperitoneal fat or possibly a benign finding such as a lipoma.

Key Points to Consider

  • For T1a kidney cancers, routine lymph node dissection is not typically recommended during surgery because of the low risk of metastasis and lack of proven survival benefit 1.
  • If there is concern about this specific area, imaging such as CT with contrast or MRI would be appropriate for further evaluation, and if suspicious, a biopsy could be considered for definitive diagnosis 1.
  • The European Association of Urology guidelines on renal cell carcinoma recommend against systematic lymph node dissection to patients with organ-confined disease, which includes T1a tumors 1.
  • The American Society of Clinical Oncology clinical practice guideline on the management of small renal masses also notes that lymph node metastasis is rare in T1a tumors 1.
  • The ACR Appropriateness Criteria for post-treatment follow-up and active surveillance of clinically localized renal cell carcinoma suggest that imaging surveillance of the chest and abdomen be performed after primary treatment for RCC, but do not specifically recommend routine evaluation of the fat anterior to the psoas muscle 1.

From the Research

Lymph Node Metastasis in Renal Cell Carcinoma

  • The provided studies do not specifically address the question of whether fat anterior to the psoas muscle below the lower pole of the left kidney is a common site for lymph node metastasis from T1a renal cell carcinoma.
  • However, study 2 discusses the role of lymph node dissection in renal cell carcinoma and notes that renal lymphatic drainage is unpredictable, making it challenging to determine the most common sites of lymph node metastasis.
  • Study 3 describes psoas lymph node metastasis in patients with carcinoma of the uterine cervix, but does not provide information on renal cell carcinoma.
  • Studies 4, 5, and 6 provide information on the clinical characteristics, treatment, and outcomes of renal cell carcinoma, but do not specifically address the question of lymph node metastasis to the fat anterior to the psoas muscle.

Sites of Metastasis in Renal Cell Carcinoma

  • Study 6 reports that the most common sites of metastasis in T1a renal cell carcinoma are bone (59%), followed by lung (35%), liver (16%), and brain (12%).
  • However, this study does not provide information on the specific location of lymph node metastasis, such as the fat anterior to the psoas muscle.

Limitations of Current Evidence

  • The available studies do not provide direct evidence to answer the question of whether fat anterior to the psoas muscle below the lower pole of the left kidney is a common site for lymph node metastasis from T1a renal cell carcinoma.
  • Further research is needed to investigate the patterns of lymph node metastasis in renal cell carcinoma and to determine the clinical significance of metastasis to specific locations, such as the fat anterior to the psoas muscle 4, 5, 6, 2, 3.

Related Questions

Is fat anterior to the psoas muscle below the lower pole of the left kidney a common site for lymph node metastasis from T1a renal cell carcinoma (kidney cancer)?
Does the fat anterior to the psoas muscle, located below the lower pole of the left kidney, lack lymph nodes and is it not a site for metastatic lymph nodes from renal (kidney) cancer?
Is fat anterior to the psoas muscle below the lower pole of the left kidney a common site for lymph node metastasis in T1a kidney cancer?
What is the significance of a 3 mm nodule located in the fat anterior to the psoas muscle below the lower pole of the left kidney, which appeared one month following partial nephrectomy for a T1a low-grade Renal Cell Carcinoma (RCC) and has remained stable over three years?
Is lymph node metastasis of kidney cancer uncommon in the perinephric fat anterior to the psoas muscle below the lower pole of the kidney?
Is fat anterior to the psoas muscle below the lower pole of the left kidney a common site for lymph node metastasis from T1a renal cell carcinoma (kidney cancer)?
What causes an increase in Dehydroepiandrosterone (DHEA)?
Is fat anterior to the psoas muscle below the lower pole of the left kidney a common site for lymph node metastasis from T1a renal cell carcinoma (kidney cancer)?
Is radiofrequency ablation (RFA) a treatment option for liver metastases of colorectal cancer according to oncology protocols?
Is fat anterior to the psoas muscle below the lower pole of the left kidney a common site for lymph node metastasis from T1a renal cell carcinoma (kidney cancer)?
What are the implications of an allergy to Dexamethasone (corticosteroid)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.